Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:
Stephens initiated coverage on Pacific Biosciences of California Inc (NASDAQ: PACB), noting a solid management team, the market opportunity of long-read, and refraining from taking over the short-read market.
William Blair analyst Louie DiPalma has initiated coverage of the shares of Boeing Company (NYSE: BA), Transdigm Group Incorporated (NYSE: TDG), and Heico Corporation